FGFR3 and urothelial carcinoma: More recently, erdafitinib, a pan-FGFR targeted inhibitor, was approved by the FDA in April 2019 for advanced urothelial carcinoma with FGFR3 hotspot mutation like S249C as the first molecularly targeted therapy [14–16].